Trials
1 active
3 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Myasthenia Gravis, Myasthenia Gravis, MuSK
- Main trialPhase 2
- “This Phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of NMD670 vs placebo in adult patients with MG with antibodies against AChR or MuSK, administered twice a day (BID) for 21 days.”In the company’s words, NCT06414954 on ClinicalTrials.gov
Other drugs for Myasthenia Gravis
- GefurulimabAlexion Pharmaceuticals, Inc. · Phase 3
- B007Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3
- Descartes-08Cartesian Therapeutics · Phase 3
- TelitaciceptRemeGen · Phase 3
- Efgartigimodargenx · Phase 3
- TelitaciceptVor Biopharma · Phase 3
Coming up1
- DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2026 | Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis | |
| Phase 2Completed | 28 Oct 2025 | Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease | |
| Phase 2Completed | 11 May 2026 | Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026